Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ABUS stock hub

Arbutus Biopharma Corporation has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ABUSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

854.7M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ABUS

In the news

Latest news · ABUS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-38.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-18.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ABUS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

203

Groups with data

Currency

USD

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001447028
Company name	Arbutus Biopharma Corporation
Country	United States
Country code	US
Cusip	03879J100
Employees	19
Employees Change	-25%
Employees Change Percent	-56.82
Enterprise value	$767.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	CA03879J1003
Last refreshed	2026-05-10
Market cap	$854.7M
Market cap category	Small-Cap
Price	$4.34
Price currency	USD
Rev Per Employee	741,210.53x
Sector	Healthcare
Sic	2834
Symbol	ABUS
Website	https://www.arbutusbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.92%
EV Sales Forward	283.92x
EV/Sales	54.49x
FCF yield	-4.64%
P/B ratio	10.91x
P/S ratio	60.69x
PS Forward	316.21x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-192.08%
EBITDA Margin	-189.51%
Gross margin	-79.23%
Gross Profit	$-11.2M
Net Income	$-33.5M
Net Income Growth Quarters	3%
Net Income Growth Years	2%
Pretax Margin	-237.88%
Profit Margin	-237.88%
Profit Per Employee	$-1.8M
ROA	-14.94
Roa5y	-24.26
ROCE	-30.53
ROE	-38.52
Roe5y	-53.76
ROIC	-18.35

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	0.45%
Cagr15y	2.75%
Cagr1y	31.94%
Cagr3y	18.62%
Cagr5y	9.08%
EPS Growth Quarters	3
EPS Growth Years	6
Revenue Growth	128.21x
Revenue Growth Q	-33.23x
Revenue Growth Years	1x
Revenue Growth3 Y	-28.8x
Revenue Growth5 Y	15.29x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.12
Assets	$94.6M
Cash	$91.5M
Current Assets	$94.5M
Current Liabilities	$6M
Debt	$4.2M
Debt Equity	$0.05
Equity	$76.6M
Interest Coverage	-278.9
Liabilities	$18M
Long Term Assets	$162,000
Long Term Liabilities	$12M
Net Cash	$87.3M
Net Cash By Market Cap	$10.21
Net Cash Growth	-25.08%
Net Debt Equity	$-1.14
Tangible Book Value	$76.6M
Tangible Book Value Per Share	$0.4
WACC	7.65

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	15.73
Net Working Capital	$-2.5M
Quick ratio	15.52
Working Capital	$88.5M
Working Capital Turnover	$0.14

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-3.23%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	4.58%
1Y total return	31.92%
200-day SMA	4.28
3Y total return	66.92%
50-day SMA	4.43
50-day SMA vs 200-day SMA	50over200
5Y total return	54.45%
All Time High	31.48
All Time High Change	-86.21%
All Time High Date	2014-03-13
All Time Low	0.82
All Time Low Change	428.37%
All Time Low Date	2019-10-21
ATR	0.18
Beta	0.62
Beta1y	0.51
Beta2y	0.24
Ch YTD	-9.77
High	4.4
High52	5.1
High52 Date	2025-09-11
High52ch	-14.9%
Low	4.31
Low52	2.94
Low52 Date	2025-05-15
Low52ch	47.62%
Ma50ch	-1.97%
Price vs 200-day SMA	1.31%
RSI	48.92
RSI Monthly	56.73
RSI Weekly	51.3
Sharpe ratio	0.75x
Sortino ratio	1.19
Total Return	-3.23%
Tr YTD	-9.77
Tr15y	50.17%
Tr1m	-2.69%
Tr1w	0.46%
Tr3m	13.02%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.06
Earnings Revenue Estimate	1,531,000x
Earnings Revenue Estimate Growth	-13.21x
Operating Income	$-27.1M
Operating margin	-192.1
Price target	$5
Price Target Change	$15.21

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	126,693,713%
Float Percent	64.33%
Shares Insiders	1.53%
Shares Institutions	50.28%
Shares Out	196,939,679
Shares Qo Q	0.3%
Shares Yo Y	3.23%
Short Float	14.05%
Short Ratio	8.93
Short Shares	9.04

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-46.6M
Average Volume	1,921,497.3x
Bv Per Share	0.4
Ch10y	4.58
Ch15y	50.17
Ch1m	-2.69
Ch1w	0.46
Ch1y	31.92
Ch3m	13.02
Ch3y	66.92
Ch5y	54.45
Ch6m	-3.56
Change	-0.23%
Change From Open	0
Close	4.35
Days Gap	-0.23
Depreciation Amortization	363,000
Dollar Volume	3,265,077.5
Earnings Date	2026-05-14
Earnings Time	bmo
EBIT	$-27.1M
EBITDA	$-26.7M
EPS	$-0.17
F Score	4
FCF	$-39.6M
FCF EV Yield	-5.16x
FCF Per Share	$-0.2
Financing CF	5,721,000
Fiscal Year End	December
Founded	2,005
Investing CF	15,580,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-23
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-23
Ma150	4.42
Ma150ch	-1.9%
Ma20	4.37
Ma20ch	-0.78%
Net CF	-18,322,000
Next Earnings Date	2026-05-22
Open	4.34
Optionable	Yes
Position In Range	34.07
Post Close	4.34
Postmarket Change Percent	1.37
Postmarket Price	$4.4
Ppne	32,000
Price Date	2026-05-08
Ptbv Ratio	11.16
Relative Volume	0.39x
Revenue	14,083,000x
SBC By Revenue	49.37x
Share Based Comp	6,953,000
Tr6m	-3.56%
Us State	Pennsylvania
Volume	752,322
Z Score	3.54

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ABUS pay a dividend?

Capital-return profile for this ticker.

Performance

ABUS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ABUS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+50.3%

Float: +64.3% of shares outstanding

Insider ownership

+1.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ABUS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

48.9

Neutral momentum band

Price vs 200-day MA

+1.3%

50/200-day relationship not available

Beta (5Y)

0.62

Less volatile than the market

Sharpe ratio

0.75

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ABUS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ABUS stock rating?

Arbutus Biopharma Corporation is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ABUS analysis?

The full report lives at /stocks/ABUS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ABUS?

The latest report frames ABUS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ABUS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.